STAAR Surgical Co
Change company Symbol lookup
Select an option...
STAA STAAR Surgical Co
G Genpact Ltd
GRTYA Guaranty Corp
SATS EchoStar Corp
$DJI Dow Jones Industrials
TIKK Tel-Instrument Electronics Corp
TEAM Atlassian Corporation PLC
PAYX Paychex Inc
FISV Fiserv Inc
PYPL PayPal Holdings Inc
Go

Health Care : Health Care Equipment & Supplies | Small Cap Growth
Company profile

STAAR Surgical Company designs, develops, manufactures and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It operates in the ophthalmic surgical market segment. Its products are intraocular lenses used in cataract surgery and implantable collamer lenses used in refractive surgery. It manufactures lenses used in corrective or refractive surgery, and makes lenses for use in surgery that treats cataracts. As of December 29, 2017, the Company sold its products in over 75 countries, with distribution in the United States, Canada, Japan and Spain.

Price
Delayed
$75.05
Day's Change
-0.0359 (-0.05%)
Bid
--
Ask
--
B/A Size
--
Day's High
75.46
Day's Low
72.83
Volume
(Light)

Today's volume of 134,388 shares is on pace to be much lighter than STAA's 10-day average volume of 471,089 shares.

134,388

DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against STAAR Surgical Company and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

8:02 am ET October 19, 2020 (Newsfile) Print

Los Angeles, California--(Newsfile Corp. - October 19, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against STAAR Surgical Company ("STAAR" or "the Company") (NASDAQ: STAA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between February 26, 2020 and August 10, 2020, inclusive (the ''Class Period''), are encouraged to contact the firm before October 19, 2020.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. STAAR is the subject of a report by investment analyst J Capital titled, "STARR Surgical, Less Than Meets the Eye." The report alleges that the Company has overstated its sales in China by at least one-third, "meaning all of the Company's $14 mln in 2019 profit is fake." The report, based on extensive interviews and research, states that the Company reports fake sales numbers and then marks up marketing costs in a scheme to hide "phantom" revenue. Based on this news, shares of STAAR fell by 6% on August 11, 2020, damaging investors.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm

Brian Schall, Esq.,

www.schallfirm.com

Office: 310-301-3335

info@schallfirm.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/66266

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.